• Delivering innovationto dermatologists.

    Delivering innovation
    to dermatologists.

    And supporting it with
    outstanding customer service.
  • Delivering innovationto dermatologists.

    Delivering innovation
    to dermatologists.

    And supporting it with
    outstanding customer service.
  • Delivering innovationto dermatologists.

    Delivering innovation
    to dermatologists.

    And supporting it with
    outstanding customer service.
  • Delivering innovationto dermatologists.

    Delivering innovation
    to dermatologists.

    And supporting it with
    outstanding customer service.

Headquartered in Malvern, Pennsylvania, Encore Dermatology, Inc. is a privately held fully-integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.

Board of Directors


William Crouse: CHAIRMAN

William Crouse is the Chairman of the Board and a Co-Founder of Encore Dermatology, Inc. William Crouse has over forty years of experience in the pharmaceutical and diagnostics industry including general management, international operations, strategic planning, licensing, acquisitions, new product development, sales, and marketing. 

Previously, Mr. Crouse was Managing Director and a General Partner of Healthcare Ventures, one of the world’s largest venture capital firms specializing in biotechnology.  Healthcare Ventures specialized in creating, financing, managing and building high science biopharmaceutical companies. Mr. Crouse is also widely-renowned for his tenure as Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International from 1987 to 1993.  Before joining Johnson & Johnson, he was Division Director at DuPont Pharmaceuticals, responsible for all international businesses and worldwide commercial development activities.  Notably, he has also served as President of Revlon Health Care Group’s companies in Latin America, Canada, and Asia/Pacific. He has also held various international sales, marketing and management positions at E.R. Squibb & Sons.

William Crouse previously served as Chairman of the Board of Precision Dermatology and currently sits on the Board of Directors for The Medicines Company. He is also on the Board of Directors of four private biotechnology companies.


Robert (Bob) J. Moccia

Bob Moccia is a co-founder of Encore Dermatology, Inc. with 15+ years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies.

Bob has over 30 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations.

Bob was most recently CEO of Precision Dermatology Inc. He has held executive management positions at Medicis Pharmaceuticals, Graceway Pharmaceuticals, and Bioglan Pharmaceuticals. He also spent time at Dermik and Stiefel Laboratories in sales, marketing and business development.


Charles Stieffel   

Charles Stiefel is a well-renowned dermatology expert and philanthropist with more than 35 years of experience in the pharmaceutical industry.  Mostly recognized for his time as Chairman and CEO of Stiefel Laboratories, Inc., a specialty dermatology company which was acquired by Glaxo SmithKline for $3.6 billion in 2009.

Charles earned his B.S. degree at Yale University and his law degree from Albany Law School.  Charles was subsequently a partner in the New York law firm of Bagley, Chadderdon, Pulver & Stiefel.  In 2003, he was awarded the Lifetime Achievement Award by the South Florida Dermatology Foundation, and in 2006 was named Ernst & Young’s Entrepreneur of the Year in Health Sciences for the State of Florida.  In 2007, he was honored with both the Distinguished Service Award by the American Academy of Dermatology and the Distinguished Corporate Leader Award by the Women’s Dermatologic Society.  In 2009, he was a global finalist in Ernst & Young’s Entrepreneur of the Year competition. In February, 2015, he received a Lifetime Achievement Award for service to dermatology at the South Beach Symposium. In April, 2015, the American Skin Association presented him with a special award for Distinguished Service to Humanity.

Since July, 2009, Charles has served as a Consultant in the pharmaceutical industry, working with several companies in the specialty pharma sector. He has donated millions of dollars in support of medical research, particularly cancer research. His gift to the Dermatology Foundation to endow the Charles & Daneen Stiefel Scholar Award was the largest gift in the history of the Dermatology Foundation. He and his wife, Daneen, also endowed the Charles and Daneen Stiefel Center for Head and Neck Cancer at MD Anderson Cancer Center in Houston. In December, 2014, he became Chairman of the Board of Brickell Biotech, Inc., a research-oriented dermatology company.


Scott Barry

Scott Barry has over 20 years of experience in investment banking and the healthcare industry. He joined EW Healthcare Partners from Novartis Pharma AG where he most recently served as the Global Head of Pharma M&A and Collaborations. In this role, he was responsible for global acquisitions, equity investments and corporate partnerships across all therapeutic areas. He joined Novartis in 2002 and held positions in the Business Development & Licensing and Mergers & Acquisitions groups.  Prior to joining Novartis, Scott was a Director for Century Capital Associates LLC, a boutique healthcare investment bank and consulting firm, where he focused on mergers & acquisitions, strategic partnering and financing transactions. Previously, he held positions at KPMG LLP in their healthcare corporate finance and assurance services groups.

Scott previously served on the Board of Directors of Orthovita, Inc. (NASDAQ: VITA) which was acquired by Stryker Corporation, and Victory Pharma, Inc., which was acquired by Shionogi, Inc. and Velcera, which was acquired by Perrigo Company. Scott currently serves on the Board of Directors for Breg/United Orthopedic Group, Encore Dermatology, Inc. and Metabolon.

Scott graduated with a Bachelor of Arts degree from Wesleyan University and a Master of Business Administration degree from New York University.

Scott joined EW Healthcare Partners as Principal in the New York office in October 2006, was promoted to Partner in 2008, and was promoted to Managing Director in June 2012.


Michael Brown

Michael is a co-founder of the company.  For 28 years, he was engaged in private law practice with regional full-service law firms.  Michael focused his practice on capital formation and mergers and acquisitions for middle market companies.  In addition to his law practice, he also served as chief information officer for two regional law firms.  Most recently, Michael managed a board of directors initiated wind down and liquidation of The Garrett Hotel Group, Inc., the owner of luxury boutique hotels located in Lake Placid, New York, Santa Fe, New Mexico and Aiken, South Carolina.

 

Leadership Team


Robert (Bob) J. Moccia  CEO

Bob Moccia is a co-founder of Encore Dermatology, Inc. with 15+ years of executive management experience as President, COO, and CEO of small to mid-sized specialty pharmaceutical companies.

Bob has over 30 years of global pharmaceutical experience with expertise in general management, operations, strategic planning, business development, product development, sales, marketing, and building customer focused organizations.

Bob was most recently CEO of Precision Dermatology Inc. He has held executive management positions at Medicis Pharmaceuticals, Graceway Pharmaceuticals, and Bioglan Pharmaceuticals. He also spent time at Dermik and Stiefel Laboratories in sales, marketing and business development.


Boris Meyerson, Ph.D.  Executive Vice President, Business Operations

Boris Meyerson is a co-founder, who spent the last 15+ years in pharmaceutical industry (mostly in dermatology) focusing on forecasting, financial planning, market access, operations and information technologies.

Most recently, Boris served as SVP, Business Operations as Onset Dermatologics (under PreCision Dermatology). He has held management positions at Graceway Pharmaceuticals and Bioglan Pharmaceuticals, and has run a successful consulting practice.

Prior to his pharmaceuticals career, he taught computer science and artificial intelligence at a university and conducted research for aerospace industry.


Kent Taylor  Vice President, Marketing

Kent brings over 23 years of dermatology and healthcare experience to Encore Dermatology, Inc. Most recently, Kent was Group Product Director of Marketing for Onset Dermatologics.

Prior to joining Onset, he was Associate Director of Marketing at Medicis, managing the Immune Franchise for the US and Canada. Kent has a proven track record delivering successful product launches, lifecycle management, executing comprehensive strategies and driving growth.

He also spent time at 3M Pharmaceuticals and Graceway Pharmaceuticals in professional relations, new product development and marketing.


Tim Waite  Vice President, Sales

Tim has over 35 years of experience in specialty pharmaceuticals, with a special focus in dermatology.

Tim began his career at Allergan Pharmaceuticals, where he spent over fifteen years working in a variety of sales leadership and marketing roles. After Tim’s time at Allegan, he joined Medicis, where he was an integral part of the company’s leadership team for the next twelve years.  At Medicis, Tim was vital in helping to build and shape what became one of the most prominent dermatology companies in the pharmaceutical industry.  Tim began his journey at Medicis as the Director of Training before he moved on to becoming the Vice President of Sales. After leaving Medicis, Tim joined Onset Dermatologics as their Vice President of Sales in 2011 and helped build the company to over $100 million in sales until it was sold to Valeant in 2014. Tim joined Encore Dermatology as their Vice President of Sales at their inception in 2015.


Chris Lesovitz  Controller

As Controller at Encore Dermatology, Inc., Chris Lesovitz is responsible for all the finance and administration functions of the company.

Chris has nearly 15 years of finance experience within the pharmaceutical industry. Prior to joining Encore, Chris was the Assistant Controller for Iroko Pharmaceuticals, LLC in Philadelphia, PA where he directed the international business operations from R&D accounting, consolidation, and reporting processes.  In the beginning of his career in finance, Chris held auditing roles of increasing responsibility within the public accounting industry.

Chris received a Bachelor of Science degree in Accounting from Villanova University and is a Certified Public Accounting in Pennsylvania.


Save

Save

Save

 

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save